



Exposure to perfluoroalkyl substances and associations with serum thyroid hormones in a remote population of Alaska Natives^{☆☆☆}



Samuel C. Byrne^{a,*}, Pamela Miller^b, Samarys Seguinot-Medina^b, Vi Waghiyi^b, C. Loren Buck^c, Frank A. von Hippel^c, David O. Carpenter^d

^a Environmental Studies, St. Lawrence University, 23 Romoda Drive, Canton, NY, USA

^b Alaska Community Action on Toxics, Anchorage, AK, USA

^c Department of Biological Sciences & Center for Bioengineering Innovation, Northern Arizona University, Flagstaff, AZ, USA

^d Institute for Health and the Environment, University at Albany, Rensselaer, NY, USA

ARTICLE INFO

Keywords:

PFAS
Thyroid
Arctic
Endocrine disruptor
Environmental justice

ABSTRACT

Perfluoroalkyl substances (PFASs) are known to accumulate in traditional food animals of the Arctic, and arctic indigenous peoples may be exposed via consumption of subsistence-harvested animals. PFASs are suspected of disrupting thyroid hormone homeostasis in humans. The aim of this study is to assess the relationship between serum PFASs and thyroid function in a remote population of Alaska Natives.

Serum samples were collected from 85 individuals from St. Lawrence Island, Alaska. The concentrations of 13 PFASs, as well as free and total thyroxine (T₄), free and total triiodothyronine (T₃), and thyrotropin (TSH) were quantified in serum samples. The relationships between circulating concentrations of PFASs and thyroid hormones were assessed using multiple linear regression fit with generalized estimating equations.

Several PFASs, including perfluorooctanoic acid (PFOA) and perfluorononanoic acid (PFNA), were positively associated with TSH concentrations when modeled individually. PFOS and PFNA were significantly associated with free T₃ and PFNA was significantly associated with total T₃ in models with PFAS*sex interactive terms; these associations suggested negative associations in men and positive associations in women. PFASs were not significantly associated with concentrations of free or total T₄.

Serum PFASs are associated with circulating thyroid hormone concentrations in a remote population of Alaska Natives. The effects of PFAS exposure on thyroid hormone homeostasis may differ between sexes.

1. Background

Perfluoroalkyl substances (PFASs) are used as industrial surfactants and in the production of waterproof or stain proof surface coatings for a variety of commercial applications. The two most widely studied PFASs, perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS), have been voluntarily phased out of use in the United States due to concerns about toxicity, and PFOS is globally restricted under the Stockholm Convention on Persistent Organic Pollutants (UNEP, 2018). PFOA and perfluorohexane sulfonate (PFHxS) are currently undergoing evaluation for inclusion in the Convention and it was determined by the expert committee that these substances meet criteria for persistence, bioaccumulation, long-range transport, and toxicity (UNEP, 2018). PFASs are not efficiently removed from the body after exposure, and the biological half-lives of PFOA, PFHxS and PFOS are

estimated to be several years (Li et al., 2018; Olsen et al., 2007).

Concentrations of PFOA and PFOS in humans are decreasing over time; the concentrations of long chain PFASs (≥8 carbons) tend to be more stable (Hurley et al., 2018; Olsen et al., 2017). Alternatives to PFASs, such as polyfluoroalkyl compounds and fluorotelomer alcohols, are known to degrade into recalcitrant PFASs, such as PFOA (Butt et al., 2014; Liu and Mejia Avendaño, 2013). Thus, long chain PFASs remain ubiquitous environmental contaminants, both due to historical releases, and continued production of precursors. Additionally, PFASs undergo atmospheric transport and deposition, as well as oceanic transport, to the Arctic (Armitage et al., 2009; Wania, 2007). Fluorotelomer alcohols are also known to undergo atmospheric transport to the Arctic, and can degrade to PFASs, specifically PFOA, perfluorononanoic acid (PFNA) and perfluoroundecanoic acid (PFUnA) (Stemmler and Lammel, 2010; Wallington et al., 2006; Young et al., 2007). Once in the Arctic, PFASs

^{☆☆} This study was approved by the Alaska Area IRB (Indian Health Service IRB00000636) and the Research Ethics Review Board of the Norton Sound Health Corporation.

[☆] This study was supported by the National Institute of Environmental Health Sciences (NIH 1R01ES019620 and 2R01ES019620).

* Corresponding author.

E-mail address: sbyrne@stlawu.edu (S.C. Byrne).

bioaccumulate in arctic biota (Butt et al., 2010; Kelly et al., 2009).

The St. Lawrence Island Yupik residents of St. Lawrence Island, Alaska rely heavily on a subsistence diet that includes many marine species including high trophic level and/or long lived marine mammals such as bowhead whale (*Balaena mysticetus*), Pacific walrus (*Odobenus rosmarus*), and bearded seal (*Erignathus barbatus*). Consumption of marine mammals is a source of exposure to persistent PFASs (Weihe et al., 2008). Consumption of caribou (*Rangifer tarandus*) is also a known source of PFAS exposure, specifically organs such as the liver (Ostertag et al., 2009). Residents of St. Lawrence Island have elevated serum concentrations of PFNA and PFUnA (Byrne et al., 2017), a pattern thought to occur due to atmospheric degradation of fluorotelomer alcohols, and subsequent bioaccumulation (Ellis et al., 2004; Rotander et al., 2012).

There is evidence that some PFASs disrupt thyroid hormone homeostasis in humans; however, the results of epidemiological studies are inconsistent with regard to strength and direction of associations. Although animal studies suggest several plausible mechanisms of these effects, their clinical significance in humans remains unclear. Among an adult Inuit population in Canada, PFOS was associated with reduced thyrotropin (TSH) and total triiodothyronine (T_3), and increased free thyroxine (T_4). In the same population, PFOS was negatively associated with thyroid binding globulin (Dallaire et al., 2009). In a heavily exposed population in the Ohio River Valley, PFOA and PFOS were positively associated total T_4 concentrations (Knox et al., 2011). In the US general population, higher exposure to PFASs has been associated with current thyroid disease (Melzer et al., 2010). However, in addition to the significant associations noted above, these studies also reported null associations between PFASs and other measures of thyroid function assessed in the study.

Due to inconsistent epidemiological associations between PFASs and measures of thyroid function, the public health significance of these compounds remains unclear. Despite a well understood dietary exposure pathway (Haug et al., 2010; Ostertag et al., 2009), Alaska Natives are poorly studied with regard to health effects of PFASs. This study aims to evaluate the associations between serum PFAS concentrations and circulating thyroid hormones in a remote population of Alaska Natives. Additionally, we address the potential for sex to modify the association between PFAS and thyroid hormones.

2. Methods

As part of a long-term study of contamination of St. Lawrence Island, Alaska (Miller et al., 2013; von Hippel et al., 2018) participants were recruited from two native villages on St. Lawrence Island, Gambell and Savoonga, during the years 2013–2014. Participants were recruited through flyers posted in public spaces, or directly by bilingual (Yupik-English) community health researchers. Inclusion criteria included being reproductive aged (18–45 years). An attempt was made to recruit a participant of the opposite sex from the same home. A total of 85 individuals from 49 homes were recruited for the study. There are a total of 36 male-female pairs from a single home, and an additional 11 unpaired women and 2 unpaired men. Structured interviews were conducted by bilingual community health researchers to collect data on participant characteristics and potential confounders. Approximately 20 ml fasting blood samples were drawn into sterile vacutainers (Becton Dickinson, Franklin Lakes, NJ), and allowed to clot at room temperature for one hour, then centrifuged for 15 min before serum was collected.

Approximately 2 ml serum aliquots were frozen in the field at -18°C and shipped overnight to Labcorp (Seattle, Washington) for analysis of thyroid hormones. TSH, total T_3 , free T_3 (fT_3), and free T_4 (fT_4) were quantified using an Electro-chemiluminescence immunoassay (ECLIA). Precision was not determined for the samples under study; however, method precision is reported as maximum observed coefficients of variation (CV) in human serum reported by

Labcorp. TSH had a maximum CV 7.1%, cross reactivity $< 0.04\%$, and an LOD of 0.005 $\mu\text{IU/ml}$. Total T_3 had a maximum CV of 5.4%, cross reactivity of $< 1\%$ for other thyroid hormones, and a limit of detection (LOD) of 0.195 ng/ml. Free T_3 had a maximum CV of 8.2%, cross reactivity of $< 0.01\%$ for other thyroid hormones, and a LOD of 0.06 ng/dl. Free T_4 had a maximum CV of 7.6%, cross reactivity of $\leq 0.005\%$ for other thyroid hormones, and a LOD of 0.101 ng/dL. Total T_4 was quantified using a cloned enzyme donor immunoassay (CEDIA) with a maximum CV of 9.2%, cross reactivity of $< 0.1\%$ for other thyroid hormones, and a LOD of 0.5–20 $\mu\text{g/dL}$. Laboratory reference intervals were 0.45–4.5 $\mu\text{IU/ml}$ for TSH, 4.5–12 $\mu\text{g/dl}$ for total T_4 , 0.82–1.77 ng/dl for fT_4 , 71–180 ng/dl for total T_3 , and 2–4.4 pg/ml for fT_3 . Serum for PFASs analyses was frozen at -20°C in pre-cleaned polypropylene falcon tubes (Becton Dickinson, Franklin Lakes, NJ) and shipped overnight to AXYS Analytical (Sydney, British Columbia, Canada). Thirteen PFASs were quantified using reverse-phase high-performance liquid chromatography/mass spectrometry (HPLC-MS) using a triple quadrupole mass spectrometer (AXYS Analytical Services Ltd., 2014). Target analytes included perfluorobutanoic acid (PFBA), perfluoropentanoic acid (PFPeA), perfluorohexanoic acid (PFHxA), perfluoroheptanoic acid (PFHpA), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnDA), perfluorododecanoic acid (PFDoA), perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), and perfluorooctane sulfonamide (PFOSA). Isotopically labelled surrogate standards were used, and a blank and matrix spike were included in each analytical batch of approximately 13 samples. Matrix spike recoveries were typically between 90% and 110%, and never outside of 80–120%. The limit of detection ranged from 0.5 to 1 ng/ml. If blanks contained quantifiable concentrations of analytes, this concentration was subtracted from the other samples in the analytical batch.

PFASs were natural log transformed in order to better fit a normal distribution. TSH was also natural log transformed. Spearman's rank correlations were used to assess unadjusted relationships among PFASs, and between PFASs and thyroid function measures. Multiple linear regression estimated with generalized estimating equations (GEE) was used to determine the influence of PFASs on circulating thyroid hormone concentrations. Several models were constructed to assess relationships between PFASs and thyroid hormone measures. Each of 4 PFASs with a detection frequency above 70% (PFOS, PFOA, PFNA, and PFUnA) were considered as the independent variable in five models, using total T_3 , fT_3 , total T_4 , fT_4 or TSH as the dependent variables, adjusted for age, sex, and smoking habits (Bertelsen and Hegedüs, 1994; Bremner et al., 2012; Kamijo et al., 1981; Suzuki et al., 2012). Confounders were identified using directed acyclic graphs (Greenland et al., 1999). Additionally, a model was constructed using PFOS, PFOA, and PFNA as covariates in a single model, for each of five thyroid measures. When the concentration of a PFAS was below the LOD, the data point was imputed as $\text{LOD}/\sqrt{2}$ for regression analysis (Hornung and Reed, 1990), because machine read values were unavailable. A sensitivity analysis was conducted in which PFASs were also modeled with data $< \text{LOD}$ imputed as the mean of observed values, a method which produces minimally biased conservative estimates (Schisterman et al., 2006). Influential observations were identified using DFBETAS which is a standardized measure of the impact of a single observation on the regression coefficient; in the event a DFBETAS was > 1 the observation was removed from the regression, and the regression was re-run. Statistical analysis was conducted in SAS 9.4 (SAS Institute, Cary, NC.). Potential effect modification by sex was assessed by adding a product term of sex (female = 1, male = 0), and the individual PFAS under study in the model along with the main effects. This study was approved by the Alaska Area IRB (Indian Health Service IRB00000636) and the Research Ethics Review Board of the Norton Sound Health Corporation.

Table 1
Descriptive statistics for study participants.

	Men (n = 38)			Women (n = 47)			Laboratory reference range
	Median	Range		Median	Range		
TSH (µIU/ml)	1.28	0.323–4.65		0.957	0.051–4.47		0.45–4.5
Total T4 (µg/dL)	9.05	4.8–13.8		8.1	4.3–11.8		4.5–12
fT4 (ng/dL)	1.3	0.95–1.71		1.23	0.94–1.67		0.82–1.77
Total T3 (pg/ml)	143.5	109–176		137	92–197		71–180
fT3 (ng/dL)	3.6	2.8–4.4		3.2	2.2–4.5		2–4.4
Age (yr)	29	19–45		28	18–45		
Smoke ^a n(%)	5 (13%)			8 (17%)			
PFASs (ng/ml)	Median	Range		Median	Range		% detect
PFOA	1.47	0.51–2.9		0.772	nd-0.44		85
PFNA	2.74	0.73–10.8		2.13	nd-12.1		98
PFUnA	0.969	nd-3.74		0.719	nd-1.73		74
PFOS	6.81	nd-16		3.35	nd-9.69		98

a = active smoking in home; nd = non-detect

3. Results

Men and women had comparable age ranges, with a median age of 29 and range of 19–45 in men, and median age of 28 and range of 18–45 in women (Table 1). Based on data from our questionnaire, smoking or environmental tobacco smoke exposure was slightly more prevalent in women (17%) than men (13%); however, this is likely underreported given that prevalence of smoking is as high as 39% in the region (Alaska Department of Health and Human Services, 2012). PFOS, PFNA and PFOA were the most frequently detected PFASs and present at the highest concentrations. PFHxS and PFDA were detected in less than half of participants (Supplemental data). There were moderate to strong statistical correlations among serum PFASs (Supplemental data). Men tended to have higher concentrations of PFASs than women (Table 1). No individuals reported current or former thyroid disease, or current thyroid medication. One individual had a TSH concentration above the reference range. Eight individuals had TSH concentrations below the reference range. One individual had both total T₃ and fT₃ concentrations above the reference ranges. Two individuals had total T₄ concentrations above the reference range, and one had total T₄ concentration below the reference range. Unless specified all other hormones in these individuals were within the reference ranges.

Table 2 presents the results for models of individual PFASs and thyroid hormones, not controlling for the presence of other PFASs. PFOA, PFNA, and PFUnA were all positively and significantly associated with TSH, indicating higher TSH concentrations were present in more exposed individuals. Table 3 presents the results of individual PFAS regression models including a PFAS_i *female sex product term. The table includes the effects of the PFAS_i in men, as well as the joint effect of the PFAS_i and female sex. Sex stratified models were unstable due to small sample size and so joint effects, the combined effect of female sex and exposure to PFAS_i due to interaction, are reported.

Table 2
Log-unit effects of individual PFASs on thyroid hormones controlling for age, sex, and smoking status.

	(ln)TSH				Total T4				fT4			
	β (95% CI)		p-value		β (95% CI)		p-value		β (95% CI)		p-value	
PFOA	0.630	0.228	1.031	< 0.005	-0.128	-1.524	1.268	0.86	-0.036	-0.138	0.066	0.49
PFOS	0.251	-0.132	0.634	0.20	-0.348	-0.977	0.282	0.28	0.004	-0.056	0.064	0.89
PFNA	0.245	0.047	0.442	0.02	-0.094	-0.712	0.524	0.77	-0.007	-0.052	0.037	0.75
PFUnA	0.324	0.075	0.573	0.01	0.354	-0.331	1.039	0.31	0.005	-0.056	0.066	0.88
	Total T3				fT3							
	β (95% CI)		p-value		β (95% CI)		p-value					
PFOA	-7.669	-18.609	3.272	0.17	-0.038	-0.271	0.196	0.75				
PFOS	-4.968	-13.311	3.376	0.24	-0.057	-0.224	0.109	0.50				
PFNA	0.662	-5.763	7.086	0.84	0.017	-0.105	0.138	0.79				
PFUnA	-2.809	-9.104	3.486	0.38	-0.098	-0.217	0.020	0.10				

There was a significant interaction between female sex and PFNA for the effect on fT₃; the effect of PFNA on fT₃ in men was negative, and the joint effect of female sex and PFNA was positive. Another significant interaction was present between sex and PFOS for the effect on fT₃; the effect of PFOS in men was negative and the joint effect in women was positive. The interaction between PFNA and sex was significant (p = 0.048) for total T₃, with a negative association for men and a positive association for the joint effect of PFNA and female sex.

Table 4 presents a single model including multiple PFASs as predictors (PFOS, PFOA and PFNA), controlling for age, sex and smoking. Only PFOA remains positively associated with TSH in the combined model. Both PFNA and PFOA were correlated with total T₃ in the combined model, and interestingly the effects were in different directions; however, these associations were not statistically significant.

4. Discussion

In the current study of adult Alaska Natives, the blood serum concentrations of multiple PFASs were positively associated with TSH concentrations. PFOA, PFNA, and PFUnA were all significantly positively associated with TSH. When PFOA, PFOS and PFNA were simultaneously modeled as predictors, only PFOA remained as having a significant positive association with TSH. This may suggest that the inter-correlation of PFASs (Supplemental data) precludes parsing the effects of individual PFASs on thyroid status with the limited sample size.

Positive associations between PFASs and TSH have been observed in PFOS-treated cynomolgus monkeys, although this was hypothesized to be a response to a decrease in T₃ (Seacat et al., 2002). Several epidemiological studies have also reported positive associations between PFASs and TSH in humans. A study of the Korean general population found that perfluorotridecanoic acid (PFTTrDA) was positively associated with serum TSH, and the association was stronger for females

Table 3
Effect of PFASs in men, and the joint effect of PFASs-female sex interaction on thyroid hormones.

	Men				Joint effect in women				
	β	95% CI		p-value	β	95% CI		[†] p-value	
					TSH				
PFOA	0.302	-0.247	0.851	0.28	0.531	-0.263	1.324	0.19	
PFOS	-0.055	-0.618	0.508	0.85	0.439	-0.182	1.061	0.17	
PFNA	0.213	-0.102	0.528	0.19	0.054	-0.387	0.495	0.81	
PFUnA	0.140	-0.214	0.495	0.44	0.436	-0.103	0.974	0.11	
					Total T4				
PFOA	-0.621	-2.461	1.219	0.51	0.803	-0.841	2.448	0.34	
PFOS	0.201	-1.096	1.499	0.76	-0.797	-2.525	0.930	0.37	
PFNA	0.164	-0.737	1.066	0.72	-0.424	-1.481	0.633	0.43	
PFUnA	0.448	-0.433	1.330	0.32	-0.250	-1.285	0.785	0.64	
					fT4				
PFOA	-0.010	-0.142	0.122	0.88	-0.043	-0.185	0.100	0.56	
PFOS	0.054	-0.036	0.145	0.24	-0.072	-0.207	0.063	0.30	
PFNA	0.005	-0.059	0.068	0.89	-0.020	-0.103	0.063	0.64	
PFUnA	0.033	-0.038	0.104	0.37	-0.072	-0.172	0.029	0.16	
					Total T3				
PFOA	-14.241	-26.241	-2.240	0.02	11.292	-5.246	27.829	0.18	
PFOS	-10.542	-22.284	1.199	0.08	8.084	-8.587	24.754	0.34	
PFNA	-5.648	-11.937	0.641	0.08	10.930	0.074	21.786	< 0.05	
PFUnA	-6.702	-13.033	-0.371	0.04	9.783	-3.539	23.104	0.15	
					fT3				
PFOA	-0.219	-0.506	0.068	0.14	0.299	-0.073	0.671	0.11	
PFOS	-0.302	-0.529	-0.074	0.01	0.352	0.050	0.653	0.02	
PFNA	-0.139	-0.283	0.005	0.06	0.265	0.062	0.467	0.01	
PFUnA	-0.174	-0.302	-0.047	0.01	0.192	-0.057	0.441	0.13	

[†] p for interaction.

than males (Ji et al., 2012). Unfortunately, PFTrDA was not measured in the current study. However, PFTrDA has been detected in numerous high trophic level arctic species at concentrations comparable to PFOA (Rotander et al., 2012; Routti et al., 2017). Future studies should assess exposure to long chain PFASs in the Arctic. Among adults in the 2007–2008 NHANES study, PFOA was positively associated with TSH concentrations (Jain, 2013). PFOS has also been positively associated with TSH in pregnant women; however, it is unclear whether these results are generalizable to non-pregnant women (Berg et al., 2017; Wang et al., 2013).

4.1. Effect modification by sex

Published literature suggests differential effects of PFASs on thyroid hormones based on sex. Among adult participants of the C8 study, participant sex significantly modified the associations between PFOS and T₄ (Knox et al., 2011). Among the Korean general population, total T₄ exhibited a significant negative association with PFTrDA, while TSH concentrations were positively associated with PFTrDA. When stratified by sex, the relationships between PFTrDA and thyroid hormones were only significant in women (Ji et al., 2012). Among participants of the

2007–2010 NHANES study, Wen et al. (2013) reported significant effects in sex stratified models. Positive associations in women were reported between PFOA and T₃, PFHxS and T₃, and PFHxS and T₄, while a negative association was reported between PFHxS and fT₄ in men (Wen et al., 2013).

In the current study, a significant interaction was found between sex and individual PFASs (Table 3). The sex of the participant significantly modified the effect of both PFOS and PFNA on fT₃. PFOS and PFNA were positively associated with fT₃ in women and negatively associated with fT₃ in men. The association between PFNA and total T₃ was also significantly modified by sex. The interaction term suggests a positive association in women and a negative association in men. Small sample sizes resulted in unstable estimates for stratified models, and these results are not reported. This could be addressed in studies with larger sample sizes.

Additionally, the significant PFAS_i*female sex product term often produced significant associations for the effect estimates in men. Effect estimates in men and women tended to be in opposite directions regardless of the hormone or PFAS under study. While this trend was only significant in select PFASs, it may be indicative of fundamental differences in how PFASs influence thyroid function in men and women.

Table 4
Log-unit effects of PFOA, PFNA, and PFOS on thyroid hormones controlling for age, sex, smoking status, and other PFASs.

(ln)TSH	Total T4				fT4								
β (95% CI)	95% CI		p-value	β (95% CI)	95% CI		p-value	β (95% CI)	95% CI		p-value		
PFOS	-0.073	-0.495	0.350	0.74	0.28	-0.425	-1.389	0.538	0.39	0.028	-0.041	0.096	0.43
PFOA	0.555	0.067	1.043	0.03	0.114	-1.619	1.847	0.90	0.90	-0.051	-0.176	0.075	0.43
PFNA	0.128	-0.113	0.370	0.30	0.049	-0.705	0.803	0.90	0.90	-0.004	-0.060	0.051	0.88
					fT3								
β (95% CI)	95% CI		p-value	β (95% CI)	95% CI		p-value						
PFOS	-5.476	-12.278	1.326	0.11	0.27	-0.091	-0.250	0.069	0.27				
PFOA	-10.291	-21.322	0.740	0.07	0.74	-0.045	-0.313	0.223	0.74				
PFNA	5.299	-0.364	10.961	0.07	0.33	0.063	-0.063	0.190	0.33				

Interestingly, women tended to have lower concentrations of PFASs than men in the study population, suggesting they may be more susceptible to PFAS induced thyroid disruption. Several sex hormones, including estrogen and human chorionic gonadotropin, can influence thyroid homeostasis, including increasing TSH expression, increasing production of thyroid hormones, as well as inhibition or induction of iodine absorption by the thyroid (D'Angelo and Fisher, 1969; Kraiem et al., 1994; Zingg and Perry, 1953). The effects of PFOS on T_3 may differ in women currently undergoing hormone replacement therapy (Shrestha et al., 2015), suggesting that estrogen or other sex hormones may play a role in the effect modification. In a study of 2011–2012 NHANES participants, PFOA and PFOS were also positively associated with T_3 , and PFOA was positively associated with fT_3 among women aged 60–80, however not in women 20–40 years of age (Lewis et al., 2015), which may suggest different mechanisms of effect pre- and post-menopause. While PFASs are not thought to be estrogenic, they are capable of promoting estrogen dependent gene expression (Sonthithai et al., 2016) and altering concentrations of both estrogen and androgens in toxicological studies (Oakes et al., 2005; Seacat et al., 2002). The specific causes of the apparent effect modification by sex have not been determined.

4.2. Modeling exposure to multiple PFASs

Typically, epidemiological studies have reported effect estimates for individual PFASs without controlling for the effects of other PFASs (Melzer et al., 2010). When PFOS, PFOA and PFNA were simultaneously modeled, only PFOA remained significantly associated with TSH. Both PFOA and PFNA tended to associate with total T_3 ; however, the directions of the effects differed. PFNA was positively correlated with total T_3 , while PFOA was negatively correlated with total T_3 . Unfortunately, the high mutual correlation in the multiple PFAS models makes interpretation difficult. The model suggests that individual PFASs may have differential effects on thyroid function, and that controlling for confounding by other PFASs would be ideal given a large enough sample size. In assays of T_3 dependent cell growth, different PFASs demonstrated differential activity, and a non-monotonic dose response curve was observed for PFHxS (Long et al., 2013). High statistical correlation among PFASs, but different biological effects may in part explain the inconsistent associations in the literature.

4.3. Role of PFASs in thyroid disruption

Toxicological studies have reported numerous mechanisms by which PFASs may alter thyroid hormone homeostasis. Select PFASs are thyroid receptor agonists, with longer chain PFASs exhibiting greater binding affinity (Ren et al., 2014). Several PFASs are known to bind with thyroid transport proteins (Jones et al., 2003; Liu et al., 2011). PFOS may increase excretion of T_4 by upregulating β -glucuronidase expression in the liver. PFOS may influence type one deiodinase concentrations, which may increase conversion of T_4 to T_3 (Weiss et al., 2009; Yu et al., 2009). Additionally, PFOS is known to upregulate OATp and MRP2 expression, which may increase active transport of thyroid hormones into cells. Additionally, the response to PFAS exposure differs by species, making extrapolation from toxicological data difficult. For example, PFOS exposure in rodents is typically associated with hypothyroxinemia (Chang et al., 2008), while in fish it has been associated with increases in T_3 (Du et al., 2009; Shi et al., 2009). Furthermore, the net impact of these various mechanisms is difficult to predict. Despite similar exposure pathways, and high correlation of serum PFASs, evidence exists for differential biological effects (Jantzen et al., 2016).

Some studies suggest there are understudied modifiers and/or mediators of the relationship between PFASs and thyroid health. An analysis of 2007–2008 NHANES data suggests that the effect of PFAS exposure on thyroid measures may be modified by autoimmune status

(TPO-ab) and iodine sufficiency (Webster et al., 2016). PFASs are also capable of altering sex hormone concentrations and sex hormone dependent gene expression (Liu et al., 2007; Oakes et al., 2005), which may indirectly impact thyroid health. While the overall weight of evidence indicates a relationship between PFASs and thyroid health, the inconsistency of the results suggests that the full complexity of this relationship is not yet understood.

Because no participants reported clinical disease, and circulating hormones did not suggest clinical thyroid disruption in any participants, the study does not support inferences about PFAS exposure and thyroid disease. However, sub-clinical thyroid disruption is associated with morbidity. Osteoporosis and changes in cardiac anatomy and physiology are more common among individuals with sub-clinical hyperthyroidism (Biondi et al., 2005), while subclinical hypothyroidism is associated with overweight and obesity (Biondi, 2010), adverse cardiovascular outcomes (Imaizumi et al., 2004; Rodondi et al., 2005), and impaired cognitive function (Osterweil et al., 1992).

4.4. Limitations

These data are cross-sectional and therefore the temporal relationship between PFASs and thyroid hormones cannot be assessed. Additionally, this was a convenience sample and therefore may not be representative of the study population. However, there is no reason to suspect that participants would have *a priori* knowledge of serum PFAS concentrations or thyroid status, making the source of bias small for these associations. The small sample size limits the number of covariates that can be simultaneously modeled while preserving power to detect associations (i.e., the study has low statistical power). It additionally complicates interpretation, as a lack of significance may not represent a lack of effect, and regression estimates may not represent population level parameters. This study presents multiple statistical tests, which could increase the probability finding false positive associations. More information on thyroid health, such as measurements of thyroid transport proteins, thyroperoxidase antibodies, and iodine sufficiency would provide a clearer picture of this complex association. Bias from competitive binding in thyroid hormone assays has been reported but is not thought to be an issue at concentrations present in human serum (Lopez-Espinosa et al., 2012).

In most cases, effects estimates from models using the mean of the observed for data < LOD produced similar, but more conservative estimates of effect. Larger percentages of missing data often resulted in greater disagreement between models. Given relatively small percentages of missing data, simple imputation can produce minimally biased effect estimates (Schisterman et al., 2006); however, a poor approximation of the variance will affect estimates of the standard error. Underestimating the standard error may artificially reduce p-values. The empirical (i.e., robust/sandwich) estimator used by GEE, based on actual within cluster variation, provides a reasonable estimate of covariance given an unknown covariance structure, but may underestimate the true standard error (Hanley et al., 2003).

Residents of St. Lawrence Island are exposed to a wide range of persistent halogenated organic compounds, many of which are known or suspected to disrupt thyroid hormone homeostasis (Byrne et al., 2015, 2018; Carpenter et al., 2005). PFASs tend to be poorly correlated with lipophilic chemicals such as polychlorinated biphenyls; this limits the potential confounding by these chemicals, but uncharacterized interactions are possible (Grandjean et al., 2012). Several PFASs, such as PFTrDA, have been associated with thyroid disruption (Ji et al., 2012), but were not measured as part of this study. Residual confounding by unmeasured PFASs is possible. This study did not measure body mass index (BMI), which may be an uncontrolled confounding variable. While other studies have reported effect modification by sex while controlling for BMI, it is possible that BMI impacted the interaction between PFAS and sex in this study.

5. Conclusion

The results of this study suggest an association between select PFASs and disruption of thyroid homeostasis. The causal relationship between PFASs and human thyroid disruption, and the clinical relevance of this relationship, remain unclear. Statistically significant relationships were present despite the lack of clinical thyroid disease in the study population. The results of this study suggest differential effects in men and women; effect modification by sex should be assessed in larger studies of PFASs and thyroid function. Associations between PFNA and thyroid function measures in this population are notable because PFNA is one of the most frequently detected PFASs in the Arctic (Muller et al., 2011). When multiple PFASs are simultaneously modeled, the strength and direction of effect estimates can be dissimilar to those of individually modeled PFASs. This study suggests a complex relationship between PFASs and thyroid homeostasis involving multiple PFASs and modified by the sex of the individual.

Acknowledgments

The authors would like to thank the many individuals who contributed to this research including Jane Kava, Jesse Golodgergen, Erika Apatiki, Kristi Apangalook, Tiffany Immingan, Millie Kingeekuk, Susie Booshu, Sharon Campbell-Aningayou, Naomi Madsen, Shelley Klein-Apatiki, Carolyn Kava, Carol Golodgergen, Bobby Ungwiluk, Kevin Zweifel, and Heidi Zimmer. The authors also thank Dr. Erin Bell, Dr. Michael Bloom, Dr. Kurunthachalam Kannan, and Dr. Lawrence Schell at the University at Albany for their comments on an early draft of the manuscript.

Conflicts of interest

The authors declare they have no actual or potential competing financial interests.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.envres.2018.06.014>.

References

- Alaska Department of Health and Social Services, 2012. Tobacco in the Great Land: a portrait of Alaska's leading cause of death update. Alaska Department of Health and Social Services, Anchorage, Alaska.
- Armitage, J.M., MacLeod, M., Cousins, I.T., 2009. Comparative assessment of the global fate and transport pathways of long-chain perfluorocarboxylic acids (PFCAs) and perfluorocarboxylates (PFCs) emitted from direct sources. *Environ. Sci. Technol.* 43, 5830–5836.
- AXYS Analytical Services Ltd., 2014. Summary of AXYS Method MLA-042 Rev 09 Ver 06: Analytical Procedure for the Analysis of Perfluorinated Organic Compounds in Blood Serum by LCMS/MS.
- Berg, V., Nost, T.H., Pettersen, R.D., Hansen, S., Veyhe, A.S., Jorde, R., Odland, J.O., Sandanger, T.M., 2017. Persistent organic pollutants and the association with maternal and infant thyroid homeostasis: a multipollutant assessment. *Environ. Health Perspect.* 125, 127–133.
- Bertelsen, J.B., Hegedüs, L., 1994. Cigarette smoking and the thyroid. *Thyroid* 4, 327–331.
- Biondi, B., 2010. Thyroid and obesity: an intriguing relationship. *J. Clin. Endocrinol. Metab.* 95, 3614–3617.
- Biondi, B., Palmieri, E.A., Klain, M., Schlumberger, M., Filetti, S., Lombardi, G., 2005. Subclinical hyperthyroidism: clinical features and treatment options. *Eur. J. Endocrinol.* 152, 1–9.
- Bremner, A.P., Feddema, P., Leedman, P.J., Brown, S.J., Beilby, J.P., Lim, E.M., Wilson, S.G., O'Leary, P.C., Walsh, J.P., 2012. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. *J. Clin. Endocrinol. Metab.* 97, 1554–1562.
- Butt, C.M., Berger, U., Bossi, R., Tomy, G.T., 2010. Levels and trends of poly- and perfluorinated compounds in the arctic environment. *Sci. Total Environ.* 408, 2936–2965.
- Butt, C.M., Muir, D.C.G., Mabury, S.A., 2014. Biotransformation pathways of fluorotelomer-based polyfluoroalkyl substances: a review. *Environ. Toxicol. Chem.* 33, 243–267.
- Byrne, S., Miller, P., Waghiyi, V., Buck, C.L., von Hippel, F.A., Carpenter, D.O., 2015. Persistent organochlorine pesticide exposure related to a formerly used defense site on St. Lawrence Island, Alaska: data from sentinel fish and human sera. *J. Toxicol. Environ. Health A* 78, 976–992.
- Byrne, S., Seguinot-Medina, S., Miller, P., Waghiyi, V., von Hippel, F.A., Buck, C.L., Carpenter, D.O., 2017. Exposure to polybrominated diphenyl ethers and perfluoroalkyl substances in a remote population of Alaska Natives. *Environ. Pollut.* 231, 387–395.
- Byrne, S.C., Miller, P., Seguinot-Medina, S., Waghiyi, V., Buck, C.L., von Hippel, F.A., Carpenter, D.O., 2018. Associations between serum polybrominated diphenyl ethers and thyroid hormones in a cross sectional study of a remote Alaska Native population. *Sci. Rep.* 8, 2198.
- Carpenter, D.O., DeCaprio, A.P., O'Hehir, D., Akhtar, F., Johnson, G., Scudato, R.J., Apatiki, L., Kava, J., Golodgergen, J., Miller, P.K., Eckstein, L., 2005. Polychlorinated biphenyls in serum of the Siberian Yupik people from St. Lawrence Island, Alaska. *Int. J. Circumpolar Health* 64, 322–335.
- Chang, S.-C., Thibodeaux, J.R., Eastvold, M.L., Ehresman, D.J., Bjork, J.A., Froehlich, J.W., Lau, C., Singh, R.J., Wallace, K.B., Butenhoff, J.L., 2008. Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS). *Toxicology* 243, 330–339.
- D'Angelo, S.A., Fisher, J.S., 1969. Influence of estrogen on the pituitary-thyroid system of the female rat: mechanisms and loci of action. *Endocrinology* 84, 117–122.
- Dallaire, R., Dewailly, E., Pereg, D., Dery, S., Ayotte, P., 2009. Thyroid function and plasma concentrations of polyhalogenated compounds in Inuit adults. *Environ. Health Perspect.* 117, 1380–1386.
- Du, Y., Shi, X., Liu, C., Yu, K., Zhou, B., 2009. Chronic effects of water-borne PFOS exposure on growth, survival and hepatotoxicity in zebrafish: a partial life-cycle test. *Chemosphere* 74, 723–729.
- Ellis, D.A., Martin, J.W., De Silva, A.O., Mabury, S.A., Hurley, M.D., SulbaekAndersen, M.P., Wallington, T.J., 2004. Degradation of fluorotelomer alcohols: a likely atmospheric source of perfluorinated carboxylic acids. *Environ. Sci. Technol.* 38, 3316–3321.
- Grandjean, P., Andersen, E.W., Budtz-Jørgensen, E., Nielsen, F., Mølbak, K., Weihe, P., Heilmann, C., 2012. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. *JAMA* 307, 391–397.
- Greenland, S., Pearl, J., Robins, J.M., 1999. Causal diagrams for epidemiologic research. *Epidemiology* 10, 37–48.
- Hanley, J.A., Negassa, A., Edwardes, M.D., Forrester, J.E., 2003. Statistical analysis of correlated data using generalized estimating equations: an orientation. *Am. J. Epidemiol.* 157, 364–375.
- Haug, L.S., Thomsen, C., Brantsæter, A.L., Kvale, H.E., Haugen, M., Becher, G., Alexander, J., Meltzer, H.M., Knutsen, H.K., 2010. Diet and particularly seafood are major sources of perfluorinated compounds in humans. *Environ. Int.* 36, 772–778.
- Hornung, R.W., Reed, L.D., 1990. Estimation of average concentration in the presence of nondetectable values. *Appl. Occup. Environ. Hyg.* 5, 46–51.
- Hurley, S., Goldberg, D., Wang, M., Park, J.-S., Petreas, M., Bernstein, L., Anton-Culver, H., Nelson, D.O., Reynolds, P., 2018. Time trends in per- and polyfluoroalkyl substances (PFASs) in California women: declining serum levels, 2011–2015. *Environ. Sci. Technol.* 52, 277–287.
- Imaizumi, M., Akahoshi, M., Ichimaru, S., Nakashima, E., Hida, A., Soda, M., Usa, T., Ashizawa, K., Yokoyama, N., Maeda, R., Nagataki, S., Eguchi, K., 2004. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. *J. Clin. Endocrinol. Metab.* 89, 3365–3370.
- Jain, R.B., 2013. Association between thyroid profile and perfluoroalkyl acids: data from NHANES 2007–2008. *Environ. Res.* 126, 51–59.
- Jantzen, C.E., Annunziato, K.A., Bugel, S.M., Cooper, K.R., 2016. PFOS, PFNA, and PFOA sub-lethal exposure to embryonic zebrafish have different toxicity profiles in terms of morphometrics, behavior and gene expression. *Aquat. Toxicol.* 175, 160–170.
- Ji, K., Kim, S., Kho, Y., Paek, D., Sakong, J., Ha, J., Kim, S., Choi, K., 2012. Serum concentrations of major perfluorinated compounds among the general population in Korea: dietary sources and potential impact on thyroid hormones. *Environ. Int.* 45, 78–85.
- Jones, P.D., Hu, W., De Coen, W., Newsted, J.L., Giesy, J.P., 2003. Binding of perfluorinated fatty acids to serum proteins. *Environ. Toxicol. Chem.* 22, 2639–2649.
- Kamijo, K., Kato, T., Saito, A., Suzuki, M., Yachi, A., 1981. Evidence of sex difference in dopaminergic modulation of serum TSH secretion in primary hypothyroidism. *Endocrinol. Jpn.* 28, 127–131.
- Kelly, B.C., Ikonou, M.G., Blair, J.D., Surridge, B., Hoover, D., Grace, R., Gobas, F.A., 2009. Perfluoroalkyl contaminants in an arctic marine food web: trophic magnification and wildlife exposure. *Environ. Sci. Technol.* 43, 4037–4043.
- Knox, S.S., Jackson, T., Frisbee, S.J., Javins, B., Ducatman, A.M., 2011. Perfluorocarbon exposure, gender and thyroid function in the C8 Health Project. *J. Toxicol. Sci.* 36, 403–410.
- Kraiem, Z., Sadeh, O., Blithe, D.L., Nisula, B.C., 1994. Human chorionic gonadotropin stimulates thyroid hormone secretion, iodide uptake, organification, and adenosine 3',5'-monophosphate formation in cultured human thyrocytes. *J. Clin. Endocrinol. Metab.* 79 (1994), 595–599.
- Lewis, R.C., Johns, L.E., Meeker, J.D., 2015. Serum biomarkers of exposure to perfluoroalkyl substances in relation to serum testosterone and measures of thyroid function among adults and adolescents from NHANES 2011–2012. *Int. J. Environ. Res. Public Health* 12, 6098–6114.
- Li, Y., Fletcher, T., Mucs, D., Scott, K., Lindh, C.H., Tallving, P., Jakobsson, K., 2018. Half-lives of PFOA, PFHxS and PFOA after end of exposure to contaminated drinking water. *Occup. Environ. Med.* 75, 46–51.
- Liu, C., Du, Y., Zhou, B., 2007. Evaluation of estrogenic activities and mechanism of action of perfluorinated chemicals determined by vitellogenin induction in primary

- cultured tilapia hepatocytes. *Aquat. Toxicol.* 85, 267–277.
- Liu, J., Mejia Avendaño, S., 2013. Microbial degradation of polyfluoroalkyl chemicals in the environment: a review. *Environ. Int.* 61, 98–114.
- Liu, W., Chen, S., Harada, K.H., Koizumi, A., 2011. Analysis of perfluoroalkyl carboxylates in vacuum cleaner dust samples in Japan. *Chemosphere* 85, 1734–1741.
- Long, M., Ghisari, M., Bonefeld-Jorgensen, E.C., 2013. Effects of perfluoroalkyl acids on the function of the thyroid hormone and the aryl hydrocarbon receptor. *Environ. Sci. Pollut. Res. Int.* 20, 8045–8056.
- Lopez-Espinosa, M.J., Fitz-Simon, N., Bloom, M.S., Calafat, A.M., Fletcher, T., 2012. Comparison between free serum thyroxine levels, measured by analog and dialysis methods, in the presence of perfluorooctane sulfonate and perfluorooctanoate. *Reprod. Toxicol.* 33, 552–555.
- Melzer, D., Rice, N., Depledge, M.H., Henley, W.E., Galloway, T.S., 2010. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. *Environ. Health Perspect.* 118, 686–692.
- Miller, P.K., Waghiyi, V., Welfinger-Smith, G., Byrne, S.C., Kava, J., Gologergen, J., Eckstein, L., Scudato, R., Chiarenzelli, J., Carpenter, D.O., Seguinot-Medina, S., 2013. Community-based participatory research projects and policy engagement to protect environmental health on St Lawrence Island, Alaska. *Int. J. Circumpolar Health* 72 21656.
- Muller, C.E., De Silva, A.O., Small, J., Williamson, M., Wang, X., Morris, A., Katz, S., Gamberg, M., Muir, D.C., 2011. Biomagnification of perfluorinated compounds in a remote terrestrial food chain: lichen-caribou-wolf. *Environ. Sci. Technol.* 45, 8665–8673.
- Oakes, K.D., Sibley, P.K., Martin, J.W., MacLean, D.D., Solomon, K.R., Mabury, S.A., Van Der Kraak, G.J., 2005. Short-term exposures of fish to perfluorooctane sulfonate: acute effects on fatty acyl-CoA oxidase activity, oxidative stress, and circulating sex steroids. *Environ. Toxicol. Chem.* 24, 1172–1181.
- Olsen, G.W., Burris, J.M., Ehresman, D.J., Froehlich, J.W., Seacat, A.M., Butenhoff, J.L., Zobel, L.R., 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. *Environ. Health Perspect.* 115, 1298–1305.
- Olsen, G.W., Mair, D.C., Lange, C.C., Harrington, L.M., Church, T.R., Goldberg, C.L., Herron, R.M., Hanna, H., Nobiletti, J.B., Rios, J.A., Reagen, W.K., Ley, C.A., 2017. Per- and polyfluoroalkyl substances (PFAS) in American Red Cross adult blood donors, 2000–2015. *Environ. Res.* 157, 87–95.
- Ostertag, S.K., Tague, B.A., Humphries, M.M., Tittlemier, S.A., Chan, H.M., 2009. Estimated dietary exposure to fluorinated compounds from traditional foods among Inuit in Nunavut, Canada. *Chemosphere* 75, 1165–1172.
- Osterweil, D., Syndulko, K., Cohen, S.N., Pettier-Jennings, P.D., Hershman, J.M., Cummings, J.L., Tourtellotte, W.W., Solomon, D.H., 1992. Cognitive function in non-demented older adults with hypothyroidism. *J. Am. Geriatr. Soc.* 40, 325–335.
- Ren, X.-M., Zhang, Y.-F., Guo, L.-H., Qin, Z.-F., Lv, Q.-Y., Zhang, L.-Y., 2014. Structure–activity relations in binding of perfluoroalkyl compounds to human thyroid hormone T3 receptor. *Arch. Toxicol.* 89, 233–242.
- Rodondi, N., Newman, A.B., Vittinghoff, E., de Rekeneire, N., Satterfield, S., Harris, T.B., Bauer, D.C., 2005. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. *Arch. Intern. Med.* 165, 2460–2466.
- Rotander, A., Kärrman, A., Bavel, B. v., Polder, A., Rigét, F., Audunsson, G.A., Vikingsson, G., Gabrielsen, G.W., Bloch, D., Dam, M., 2012. Increasing levels of long-chain perfluorocarboxylic acids (PFCAs) in arctic and North Atlantic marine mammals, 1984–2009. *Chemosphere* 86, 278–285.
- Routti, H., Aars, J., Fuglei, E., Hanssen, L., Lone, K., Polder, A., Pedersen, Å.Ø., Tartu, S., Welker, J.M., Yoccoz, N.G., 2017. Emission changes dwarf the influence of feeding habits on temporal trends of per- and polyfluoroalkyl substances in two arctic top predators. *Environ. Sci. Technol.* 51, 11996–12006.
- Schisterman, E.F., Vexler, A., Whitcomb, B.W., Liu, A., 2006. The limitations due to exposure detection limits for regression models. *Am. J. Epidemiol.* 163, 374–383.
- Seacat, A.M., Thomford, P.J., Hansen, K.J., Olsen, G.W., Case, M.T., Butenhoff, J.L., 2002. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. *Toxicol. Sci.* 68, 249–264.
- Shi, J., Liu, C., Wu, G., Zhou, B., 2009. Waterborne exposure to PFOS causes disruption of the hypothalamus–pituitary–thyroid axis in zebrafish larvae. *Chemosphere* 77, 1010–1018.
- Shrestha, S., Bloom, M.S., Yucel, R., Seegal, R.F., Wu, Q., Kannan, K., Rej, R., Fitzgerald, E.F., 2015. Perfluoroalkyl substances and thyroid function in older adults. *Environ. Int.* 75, 206–214.
- Sonthithai, P., Suriyo, T., Thiantanawat, A., Watcharasi, P., Ruchirawat, M., Satayavivad, J., 2016. Perfluorinated chemicals, PFOS and PFOA, enhance the estrogenic effects of 17 β -estradiol in T47D human breast cancer cells. *J. Appl. Toxicol.* 36, 790–801.
- Stemmler, I., Lammel, G., 2010. Pathways of PFOA to the Arctic: variabilities and contributions of oceanic currents and atmospheric transport and chemistry sources. *Atmos. Chem. Phys.* 10, 9965–9980.
- Suzuki, S., Nishio, S.-i., Takeda, T., Komatsu, M., 2012. Gender-specific regulation of response to thyroid hormone in aging. *Thyroid Res.* 5, 1–8.
- UNEP, 2018. Stockholm Convention on Persistent Organic Pollutants.
- von Hippel, F.A., Miller, P.K., Carpenter, D.O., Dillon, D., Smayda, L., Katsiadaki, I., Titus, T.A., Batzel, P., Postlethwait, J.H., Buck, C.L., 2018. Endocrine disruption and differential gene expression in sentinel fish on St. Lawrence Island, Alaska: health implications for indigenous residents. *Environ. Pollut.* 234, 279–287.
- Wallington, T.J., Hurley, M.D., Xia, J., Wuebbles, D.J., Sillman, S., Ito, A., Penner, J.E., Ellis, D.A., Martin, J., Mabury, S.A., Nielsen, O.J., Sulbaek-Andersen, M.P., 2006. Formation of C7F15COOH (PFOA) and other perfluorocarboxylic acids during the atmospheric oxidation of 8:2 fluorotelomer alcohol. *Environ. Sci. Technol.* 40, 924–930.
- Wang, Y., Starling, A.P., Haug, L.S., Eggesbo, M., Becher, G., Thomsen, C., Travlos, G., King, D., Hopkin, J.A., Rogan, W.J., Longnecker, M.P., 2013. Association between perfluoroalkyl substances and thyroid stimulating hormone among pregnant women: a cross-sectional study. *Environ. Health* 12, 76–83 (-76).
- Wania, F., 2007. A global mass balance analysis of the source of perfluorocarboxylic acids in the Arctic ocean. *Environ. Sci. Technol.* 41, 4529–4535.
- Webster, G.M., Rauch, S.A., Ste, M.N., Mattman, A., Lanphear, B.P., Venners, S.A., 2016. Cross-sectional associations of serum perfluoroalkyl acids and thyroid hormones in U.S. adults: variation according to TPOAb and iodine status (NHANES 2007–2008). *Environ. Health Perspect.* 124, 935–942.
- Weihe, P., Kato, K., Calafat, A.M., Nielsen, F., Wanigatunga, A.A., Needham, L.L., Grandjean, P., 2008. Serum concentrations of polyfluoroalkyl compounds in Faroese whale meat consumers. *Environ. Sci. Technol.* 42, 6291–6295.
- Weiss, J.M., Andersson, P.L., Lamoree, M.H., Leonards, P.E.G., van Leeuwen, S.P.J., Hamers, T., 2009. Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin. *Toxicol. Sci.* 109, 206–216.
- Wen, L.L., Lin, L.Y., Su, T.C., Chen, P.C., Lin, C.Y., 2013. Association between serum perfluorinated chemicals and thyroid function in U.S. adults: the National Health and Nutrition Examination Survey 2007–2010. *J. Clin. Endocrinol. Metab.* 98 (2013), E1456–E1464.
- Young, C.J., Furdui, V.I., Franklin, J., Koerner, R.M., Muir, D.C.G., Mabury, S.A., 2007. Perfluorinated acids in arctic snow: new evidence for atmospheric formation. *Environ. Sci. Technol.* 41, 3455–3461.
- Yu, W.-G., Liu, W., Jin, Y.-H., 2009. Effects of perfluorooctane sulfonate on rat thyroid hormone biosynthesis and metabolism. *Environ. Toxicol. Chem.* 28, 990–996.
- Zingg, W., Perry, W.F., 1953. The influence of adrenal and gonadal steroids on the uptake of iodine by the thyroid gland. *J. Clin. Endocrinol. Metab.* 13, 712–723.